Dengue and West Nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
US8859240B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 2, 2009 |
| Grant date | Oct 14, 2014 |
| Priority date | — |
| Expiry date | Aug 15, 2033 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.